Summary
Clinical results of tamoxifen (‘Nolvadex’-ICI) monotherapy in 44 premenopausal women with advanced breast cancer have been reviewed. Objective tumor regression was achieved in 12 (27%) patients and a further 10 (22%) were classified as ‘stabilized’. Median duration of response was 12.7 months at the time of analysis. Greatest benefits occurred in soft tissue dominant and receptor-positive tumors, but there was no correlation between tumor response and other clinical manifestations of estrogen deprivation (e.g. menstrual disturbance, hot flushes).
The benefits of conventional doses of tamoxifen do not therefore appear to be influenced by menopausal status and compare favorably to achievements reported after surgical oophorectomy.
References
Treves N, Finkbeiner JA: An evaluation of therapeutic surgical castration in the treatment of metastatic recurrent and primary inoperable mammary carcinoma in women. Cancer 11: 421–439, 1958
Block GE, Lampe I, Vial AB, Coller FA: Therapeutic castration for advanced mammary cancer. Surgery 47: 877–884, 1960
Dao TL: Site of metastases and response to therapy in women with cancer of the breast. Acta UICC 18: 928–940, 1962
Taylor SG: Endocrine ablation in disseminated mammary carcinoma. Surg Gynecol Obstet 115: 443–48, 1962
Veronesi V, Pizzocaro G, Rossi A: Oophorectomy for advanced carcinoma of the breast. Surg Gynecol Obstet 141: 569–70, 1975
Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE: Tamoxifen.In Goldberg ME (ed): Pharmacological and Biochemical Properties of Drug Substances. APA, Washington, 1979, pp 355–399
Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978
Patterson JS, Edwards DG, Battersby LA: A review of the international clinical experience with tamoxifen. Jap J Cancer Clinics Suppl: 157–183, 1981
Manni A, Pearson OH: Antioestrogen induced remissions in premenopausal women with Stage IV breast cancer — effects on ovarian function. Cancer Treat Rep 64: 779–785, 1980
Pritchard KI, Thomson BD, Myers RE, Sutherland DJA, Mobbs BG, Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796, 1980
Margreiter R: Die antioestrogene Substanz Tamoxifen in der Behandlung des fortgeschrittenen Mammakarzinoms. Langenbecks Arch Chir 351: 249–262, 1980
Haywood JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens AD: Assessment of response to therapy in advanced breast cancer. Eur J Canc 13: 89–94, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Margreiter, R., Wiegele, J. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Tr 4, 45–48 (1984). https://doi.org/10.1007/BF01806987
Issue Date:
DOI: https://doi.org/10.1007/BF01806987